Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 2/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1367919 | 1.00 | NTRK1 (0.40) | NTRK1MAPK14CSF1RGPR55LIPG | |
| SCHEMBL1368867 | 0.90 | PTGER4 (0.43) | NTRK1MAPK14CSF1RNPC1 | |
| SCHEMBL1368868 | 0.90 | PTGER4 (0.43) | NTRK1MAPK14CSF1RNPC1 | |
| SCHEMBL1367405 | 0.89 | SCN9A (0.43) | NTRK1CSF1RGPR55PRCPHTT | |
| SCHEMBL27831875 | 0.83 | NTRK1 (0.41) | NTRK1MAPK14CSF1RGPR55LIPG | |
| SCHEMBL1365910 | 0.81 | NTRK1 (0.47) | NTRK1MAPK14GPR55P2RX3 | |
| SCHEMBL1365913 | 0.81 | NTRK1 (0.47) | NTRK1MAPK14GPR55P2RX3 | |
| SCHEMBL1366562 | 0.80 | GPR55 (0.48) | NTRK1MAPK14GPR55 | |
| SCHEMBL1366564 | 0.80 | GPR55 (0.48) | NTRK1MAPK14GPR55 | |
| SCHEMBL19690901 | 0.79 | EGFR (0.46) | HTTNPC1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673891-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2394999-B1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2014-01-29 | — | — | EP | disclosed |
| US-8586591-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20130131082-A1 | Aminopyrazine Derivative and Medicine | NIPPON SHINYAKU CO., LTD (JP) | 2013-05-23 | — | — | US | disclosed |
| EP-2394999-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110288065-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131082-A1 | Aminopyrazine Derivative and Medicine | MC2R, AGTR2, AGTR1 | NTRK1 1477/4885MAPK14 3835/4885CSF1R 365/4885 |
| US-20110288065-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | MC2R, CNR1, NPY2R | NTRK1 1475/4885MAPK14 3642/4885CSF1R 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.